AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02774642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene-PE
Description: The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
Study NCT03240263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK
Study NCT03240263 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endurance training
Description: Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK
Study NCT03819894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Introduction of a lower female hs-cTn threshold
Description: The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
Study NCT04127799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjects with AF conventional treatment
Description: Subjects with standardized treatment according to latest guidelines via conventional visit.
Study NCT04127799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjects with AF conventional treatment
Description: Subjects with standardized treatment according to latest guidelines via conventional visit.
Study NCT01779869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
Study NCT04348019 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: Fasting was defined as no foods or caloric beverages.
Study NCT04348019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting was defined as no foods or caloric beverages.
Study NCT03837665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
Study NCT02794987 — intervention group
Intervention type: DEVICE
Intervention: SpyGlass® choledoscopy
Description: Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
Study NCT06606288 — intervention group
Intervention type: DEVICE
Intervention: Conduction system pacing
Description: Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
Study NCT06606288 — intervention group
Intervention type: DEVICE
Intervention: Bi-ventricular pacing
Description: Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
Study NCT01248754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical neuronavigation with 18F-DOPA PET imaging
Description: Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
Study NCT05063188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage
Description: Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
Study NCT05063188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical pilates exercises
Description: Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
Study NCT05063188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical pilates exercises
Description: Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
Study NCT03687411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuraxial ultrasonography
Description: Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
Study NCT02849938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TytoCare Device
Description: Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
Study NCT00237640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cinnamon or placebo 500 mg capsule twice daily
Description: Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
Study NCT00237640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamon or placebo 500 mg capsule twice daily
Description: Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
Study NCT03997279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
Study NCT03997279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
Study NCT02494843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online Hemodiafiltration
Description: Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
Study NCT02494843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
Study NCT03861572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training
Description: Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
Study NCT03861572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional eccentric training
Description: Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
Study NCT02796872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GOS
Description: GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
Study NCT02796872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-GOS 3%
Description: Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
Study NCT02796872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-GOS 2%
Description: Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
Study NCT02796872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mother's breast milk
Description: exclusively breastfed infants for at least 7 days prior to enrollment
Study NCT00387738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Description: Escalating doses, 6 weekly subcutaneous (under the skin) injections
Study NCT00387738 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Histamine base
Description: Escalating doses, 6 weekly subcutaneous (under the skin) injections
Study NCT04710407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
Study NCT00993109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalat (Nifedipine, BAYA1040)
Description: Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
Study NCT00993109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan (Valsartan)
Description: Valsartan 160 mg OM (Two Valsartan 80mg tablets)
Study NCT00481325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pexacerfont
Description: Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
Study NCT00481325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
Study NCT00481325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
Study NCT00823745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-PF-00868554
Description: solution, single dose
Study NCT01919047 — intervention group
Intervention type: DRUG
Intervention: Betanis
Description: Oral
Study NCT02217371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h).
Study NCT02217371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological tests
Description: The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h).
Study NCT03148145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Goal Delivery by Smartphone
Description: Step Goal Delivery by Smartphone
Study NCT03148145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Goal Delivery by Smartphone
Description: Step Goal Delivery by Smartphone
Study NCT03148145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Delivery by Smartphone
Description: Message Delivery by Smartphone
Study NCT01338077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alginate
Description: oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
Study NCT01338077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20 mg capsule, 1 capsule once daily, 4 weeks
Study NCT02621177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607
Description: For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
Study NCT02621177 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal S1
Description: For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
Study NCT05639101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Decission support system management & mobile App Intervention Group
Description: The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms.
Study NCT01068951 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
Study NCT01724567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
Study NCT01724567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
Study NCT00905554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warm water irrigation
Description: warm water irrigation during insertion phase of colonoscopy
Study NCT00905554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air insufflation
Description: air insufflation during the insertion phase of colonoscopy
Study NCT04840290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
Description: Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
Study NCT00488345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tygacil
Study NCT04411589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnifying endoscopy with optical enhancement system
Description: A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
Study NCT04411589 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light endoscopy system
Description: A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
Study NCT02946047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 1 MG
Description: 1 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 1 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
Study NCT03110757 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Virus Vaccine (Recombinant)
Description: A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
Study NCT03110757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel
Description: Sm-TSP-2/Alhydrogel
Study NCT02136264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCFA interventional dietary counselling
Study NCT02136264 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional DASH diet counselling
Study NCT00424463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
Study NCT00424463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-186
Description: Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
Study NCT00963820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib citrate
Description: Ixazomib citrate capsules
Study NCT02219516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Study NCT02022592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Study NCT03150069 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: In-person or telephone in-depth interview
Study NCT01534130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
Study NCT01534130 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
Study NCT00338273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
Study NCT00338273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Study NCT01326923 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Single arm phase II study of chemotherapy
Study NCT05227963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization
Description: In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
Study NCT01218451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group C polysaccharide conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh
Study NCT01218451 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group C polysaccharide conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh